Bevacizumab biosimilars are near-identical copies of the cancer drug bevacizumab (originally marketed as Avastin) that have been approved by regulators after demonstrating they match the original in structure, biological activity, clinical effectiveness, and safety. Multiple biosimilar versions are now available worldwide, and head-to-head trials consistently show no meaningful differences in tumor response, survival, or side effects compared with the reference product. For patients and oncologists, the practical significance is straightforward: these alternatives deliver the same therapeutic benefit at a lower cost, and the evidence behind that claim is unusually thorough.
What Bevacizumab Does and Why Copying It Is Hard
Bevacizumab is a monoclonal antibody that targets vascular endothelial growth factor (VEGF), a protein tumors use to recruit new blood vessels. By blocking VEGF, the drug starves tumors of their blood supply through several routes: it prevents new vessels from growing, causes recently formed tumor blood vessels to shrink, changes how blood flows through surviving vessels, and may even act directly on tumor cells themselves.1Seminars in Oncology. Mechanisms of Action of Bevacizumab as a Component of Therapy for Metastatic Colorectal Cancer That multi-pronged action is why bevacizumab is used across a range of cancers, from colorectal and lung to ovarian and kidney.
Copying a monoclonal antibody is fundamentally different from copying a simple pill. Small-molecule generics are chemically identical to their originals because the molecules are tiny and easy to synthesize. Antibodies, by contrast, are enormous proteins produced inside living cells. Slight differences in the cell line, growth conditions, or purification process can change the molecule’s shape, sugar coatings, and stability in ways that potentially affect how it works in the body.2Europe PMC / Einstein (São Paulo). Why are biosimilars much more complex than generics? That complexity is why regulators created a separate approval pathway for biosimilars, requiring far more testing than a generic aspirin would ever need.
How Regulators Decide a Biosimilar Is Close Enough
The approval pathway for a bevacizumab biosimilar rests on what regulators call the “totality of evidence.” That phrase sounds bureaucratic, but it describes a genuinely layered process. Developers must show their product matches the original across analytical, functional, and clinical comparisons, and a clinical study in at least one relevant patient population must confirm that any remaining differences are too small to matter. Once biosimilarity is demonstrated in one cancer type, regulators can then extrapolate approval to the other cancers the original treats, even without running trials in each one.3PubMed. Bevacizumab biosimilars: scientific justification for extrapolation of indications
Extrapolation is a concept that sometimes worries patients: how can a drug be approved for colon cancer based on a lung cancer trial? The logic hinges on the fact that the biosimilar works through the same mechanism in every tumor type. If the molecule binds VEGF the same way as the original, and it behaves identically in the body, there is no biological reason it would perform differently in one cancer versus another. One approved biosimilar, SB8, followed this path and is now used across all the tumor types the original covers.4PubMed. SB8, an approved bevacizumab biosimilar based on totality of evidence: scientific justification of extrapolation
Analytical Testing: Matching the Molecule Itself
Before any patient receives a bevacizumab biosimilar in a trial, developers spend years comparing the physical and functional properties of their molecule against the original. These comparisons are exhaustive and constitute the foundation of every biosimilar application. The goal is to show that the two molecules are, for all practical purposes, the same object.
One biosimilar candidate, BAT1706, was tested for its ability to bind multiple forms of VEGF-A. Its binding activity to the most common VEGF isoform came in at about 96% of the reference product’s activity, and the confidence intervals for that comparison fell within prespecified equivalence margins. Binding to other VEGF-A isoforms and the kinetics of how quickly the molecule latched on and let go were also comparable.5PubMed Central. Physicochemical and Functional Similarity Assessment Between Proposed Bevacizumab Biosimilar BAT1706 and Reference Bevacizumab Another candidate, BVZ-BC, was put through an even broader battery of tests covering amino acid sequence, sugar profiles, protein structure, purity, and biological activity through multiple independent assays, and matched the original on every attribute examined.6Analytical Chemistry. Analytical Similarity of a Proposed Biosimilar BVZ-BC to Bevacizumab A third candidate, MYL-1402O, showed comparable activity in cell-based assays measuring how well it blocked VEGF from triggering blood vessel growth and receptor signaling.7PubMed. Analytical similarity assessment of MYL-1402O to reference Bevacizumab
The consistency of these findings across different biosimilar products and different testing platforms is worth noting. It suggests that the analytical standards regulators have set are rigorous enough to reliably filter out products that don’t match, while still being achievable for manufacturers who invest in the science.
Clinical Trials Show Equivalent Effectiveness
Analytical similarity is necessary but not sufficient; regulators also require head-to-head clinical trials. The pivotal study design for most bevacizumab biosimilars involves randomizing patients with advanced non-squamous non-small cell lung cancer to either the biosimilar or the original, both given alongside chemotherapy. Lung cancer is a common choice because bevacizumab’s contribution to response rates is well characterized in that setting, making it easier to detect any meaningful difference.
In the MAPLE trial, one of the largest such studies, patients receiving the biosimilar ABP 215 had an objective response rate of 39%, compared with about 42% for patients on the original bevacizumab. The risk ratio for response was 0.93, and the confidence interval fell well within the pre-established equivalence boundaries.8PubMed. Efficacy and Safety of the Biosimilar ABP 215 Compared with Bevacizumab in Patients with Advanced Nonsquamous Non-small Cell Lung Cancer (MAPLE) Those margins were set before the trial began: if the response-rate ratio stayed between 0.67 and 1.5, the two treatments would be considered clinically equivalent. The actual result landed squarely in the middle.9PubMed Central. The Totality of Evidence and Use of ABP 215, a Biosimilar to Bevacizumab
The STELLA trial followed a similar design with a different biosimilar, MB02, and reached the same conclusion: no clinically meaningful differences in effectiveness or safety.10PubMed Central. Efficacy, Safety and Immunogenicity of MB02 (Bevacizumab Biosimilar) versus Reference Bevacizumab in Advanced Non-Small Cell Lung Cancer: A Randomized, Double-Blind, Phase III Study (STELLA) A systematic review and meta-analysis pooling data from multiple such trials confirmed that rates of common side effects, including high blood pressure, protein in the urine, low white blood cell counts, and nausea, did not differ between biosimilar and original bevacizumab groups.11PubMed Central. Comparison of efficacy and safety of bevacizumab biosimilar and original bevacizumab in non-squamous non-small cell lung cancer: a systematic review and meta-analysis
Immunogenicity and the Antibody-Against-the-Antibody Question
One concern specific to biologic drugs is immunogenicity: the possibility that the patient’s immune system will produce antibodies against the therapeutic antibody itself. If that happens, the drug can be neutralized or trigger reactions. Because biosimilars are produced in different cell lines than the original, even tiny structural differences could theoretically provoke different immune responses.
In practice, rates of anti-drug antibodies with bevacizumab biosimilars have been low and comparable to the original. In one large trial of the biosimilar TAB008, anti-drug antibodies appeared in about 1% of biosimilar patients and about 2% of patients on the original, with a single neutralizing antibody case in the original bevacizumab group that resolved on follow-up.12PubMed Central. Bevacizumab biosimilar candidate TAB008 compared to Avastin® in patients with locally advanced, metastatic EGFR wild-type non-squamous non-small cell lung cancer The STELLA trial likewise reported similar rates of anti-drug and neutralizing antibodies across both arms.13PubMed Central. Efficacy, Safety and Immunogenicity of MB02 (Bevacizumab Biosimilar) versus Reference Bevacizumab in Advanced Non-Small Cell Lung Cancer: A Randomized, Double-Blind, Phase III Study (STELLA) These numbers are reassuring, though long-term surveillance data will continue to accumulate as more patients are treated.
Switching Mid-Treatment
Clinical trials typically enroll patients who start on a biosimilar from day one. But in the real world, many patients begin treatment on the original bevacizumab and are later switched to a biosimilar, often because of formulary changes at their hospital or insurance plan. The practical question for those patients is whether switching mid-course introduces any new risk.
A real-world study of patients with metastatic colorectal cancer who switched from original bevacizumab to the biosimilar bevacizumab-awwb found no concerning signals. Among patients who switched, median progression-free survival from the start of first-line therapy was about 14 months, and median overall survival was about 26 months, figures that align with historical expectations for that population. Only about 4% experienced events of interest such as blood clots, protein in the urine, or infusion reactions after switching, and none of those events resulted in death.14PubMed Central. Real-world outcomes among patients with metastatic colorectal cancer treated first line with a bevacizumab biosimilar (bevacizumab-awwb)
In the United States, the formal concept of interchangeability goes a step further. If a biosimilar earns an interchangeability designation from the FDA, pharmacists can substitute it for the original without the prescribing physician’s direct involvement, depending on state law.15Journal of Law and the Biosciences. Competition law and pricing among biologic drugs: the case of VEGF therapy for retinal diseases Not all bevacizumab biosimilars have pursued this designation, but the clinical switching data provide a practical safety net regardless of the regulatory label.
The Cost Difference
Cost is the driving reason biosimilars exist. Bevacizumab is one of the most expensive cancer drugs by total spending, given how widely it is used and how long treatment courses run. Biosimilar versions are priced lower, and health-system savings grow as adoption increases.
A U.S. budget impact analysis estimated that even modest market shifts toward the biosimilar bevacizumab-bvzr would save a commercial payer about $7 million over five years, and Medicare about $4 million over the same period.16PubMed Central. Does Biosimilar Bevacizumab Offer Affordable Treatment Options for Cancer Patients in the USA? A Budget Impact Analysis from US Commercial and Medicare Payer Perspectives A cost-effectiveness study using real-world data found that biosimilars saved roughly $6,400 per patient compared with the original, with no measurable difference in survival or quality-adjusted life-years.17PubMed. Cost-Effectiveness Analysis of Bevacizumab Biosimilars Versus Originator Bevacizumab for Metastatic Colorectal Cancer
In Spain, a budget impact analysis projected that moving 80% of patients to biosimilars by year three would save the healthcare system over €52 million annually on bevacizumab alone, a reduction of nearly 14% in total pharmaceutical costs for that drug.18European Journal of Hospital Pharmacy. Budget impact analysis of bevacizumab biosimilars for cancer treatment in adult patients in Spain These per-patient and system-level savings are not trivial for a drug that can cost tens of thousands of dollars per treatment course.
Adoption Barriers and Geographic Variation
Despite the evidence and cost advantages, uptake of bevacizumab biosimilars has been uneven. A study of Medicare Part B claims from 2019 to 2023 found socioeconomic and geographic variation in biosimilar adoption, with certain regions lagging behind. The authors concluded that closing these gaps would require coordinated efforts around drug delivery logistics, reimbursement structures, and clinician-level hesitancy.19JCO Oncology Practice. Adoption of Bevacizumab Biosimilars in Medicare Part B: Socioeconomic and Geographic Variation, 2019–2023
On the clinician side, a survey of community oncology practices found that perceived barriers to biosimilar use were actually moderately low overall, with the highest concern being payer-related issues like insurance coverage and reimbursement rates rather than doubts about the science. The average biosimilar utilization rate in the surveyed practices was about 66%, with practices in the western U.S. reaching roughly 72%.20Journal of the American Pharmacists Association. Provider perceptions of barriers to biosimilar utilization in community oncology practices That’s a meaningful fraction, but it means a third of eligible patients were still receiving the costlier original. Interestingly, perceptions of barriers didn’t actually correlate with how often a practice used biosimilars, suggesting that individual habit and institutional inertia matter more than any specific concern.
Patent thickets have also delayed biosimilar availability, particularly in the United States. On average, about 16 patents are asserted against each biosimilar entering the U.S. market, compared with fewer than two in Canada or the U.K. The result is an average delay of nearly three years between FDA approval and actual biosimilar launch in the U.S., versus seven months in Canada and under five months in the U.K.21PubMed Central. Biological patent thickets and delayed access to biosimilars, an American problem Supply chain issues and commercial decisions play a role too, but the sheer volume of patent litigation in the U.S. is the most visible bottleneck.
Bevacizumab Biosimilars in Liver Cancer Combination Regimens
One of the more consequential clinical developments in recent years has been the pairing of immune checkpoint inhibitors with anti-VEGF therapy for advanced liver cancer. Several trials have used bevacizumab biosimilars as the anti-VEGF component in these combinations, and the results have been striking enough to reshape treatment guidelines in some countries.
The ORIENT-32 trial randomized patients with advanced hepatocellular carcinoma to receive the PD-1 inhibitor sintilimab plus a bevacizumab biosimilar or sorafenib, the previous standard of care. Progression-free survival was significantly longer in the combination arm (about 4.6 versus 2.8 months), and at the first interim analysis, overall survival was also significantly better, with a hazard ratio of 0.57. The most common serious side effect in the combination group was hypertension, occurring in about 14% of patients.22The Lancet Oncology. Sintilimab plus bevacizumab biosimilar versus sorafenib as first-line treatment for advanced hepatocellular carcinoma (ORIENT-32)
A second randomized trial tested a different PD-1 inhibitor (SCT-I10A) plus a different bevacizumab biosimilar (SCT510) against sorafenib. The combination achieved a median overall survival of about 22 months versus 14 months for sorafenib, with an objective response rate of roughly 33% compared with just 4% on sorafenib.23Journal of Clinical Oncology. SCT-I10A combined with a bevacizumab biosimilar (SCT510) versus sorafenib in the first-line treatment of advanced hepatocellular carcinoma Real-world data from a Chinese multicenter study confirmed that the sintilimab-plus-biosimilar combination produced response rates above 50% in patients with preserved liver function, though patients with more impaired liver function had shorter survival despite similar response rates.24PubMed Central. Sintilimab plus a bevacizumab biosimilar (IBI305) in advanced HCC with Child-Pugh A/B liver function
These results matter beyond liver cancer. They demonstrate that biosimilar bevacizumab performs well not only as a standalone anti-VEGF agent but also as a partner in combination immunotherapy, a treatment approach that is expanding rapidly into other tumor types.
Off-Label Use in Eye Conditions
Bevacizumab has been used off-label for eye conditions for nearly two decades. Ophthalmologists inject tiny doses directly into the eye to treat conditions where abnormal blood vessel growth threatens vision, including wet age-related macular degeneration, diabetic macular edema, and retinal vein occlusions. The original product was eventually discontinued in some markets, creating a natural need for the biosimilar version.
A retrospective Australian study examined the safety of intravitreal injections of the bevacizumab biosimilar MVASI across more than 6,200 injections. The most common indications were wet macular degeneration and diabetic macular edema, accounting for about 60% of injections combined.25Clinical & Experimental Ophthalmology. Safety of an Intravitreal Bevacizumab Biosimilar (MVASI) This is still an off-label use, since no bevacizumab product is formally approved for eye injections, and the repackaging of a drug intended for intravenous use into tiny ophthalmic doses introduces its own handling concerns. But for clinicians who have long relied on bevacizumab as an affordable alternative to purpose-built eye drugs, the biosimilar fills a critical gap.
Manufacturing Consistency Over Time
A less obvious but important concern with any biologic is whether the product stays consistent from batch to batch over months and years. Even after approval, manufacturing drift can occur. A study of bevacizumab products marketed in Spain examined protein content and dimer formation (aggregates of two antibody molecules stuck together, which can affect potency and immunogenicity) across the original and biosimilar versions. The process capability index for protein content exceeded the 4-sigma quality threshold commonly used in pharmaceutical manufacturing, confirming tight batch-to-batch consistency.26PubMed Central. Assessing Protein Content and Dimer Formation in the Bevacizumab Reference Product and Biosimilar Versions Marketed in Spain For patients, that kind of quality control translates into confidence that the vial they receive six months into treatment is the same as the one they received on day one.
Access in Lower-Income Countries
Bevacizumab biosimilars carry special significance in lower-income countries where the original drug’s price often puts it out of reach entirely. Initiatives like the Clinton Health Access Initiative’s Cancer Access Partnership have negotiated pricing agreements covering bevacizumab and several other cancer biologics in parts of sub-Saharan Africa and Asia.27The Lancet Global Health. Expanding access to biotherapeutics in low-income and middle-income countries through intellectual property licensing and technology transfer Biosimilar availability broadens the supply base and creates competitive pressure that can push prices down further. In many of these settings, the question is not “original versus biosimilar” but “biosimilar versus no treatment at all,” which reframes the value proposition entirely. The clinical evidence accumulated in high-income-country trials gives regulators in these markets a strong foundation for approving and recommending biosimilar versions without needing to repeat large trials locally.